Know Cancer

or
forgot password


N/A
18 Years
N/A
Open (Enrolling)
Both
Circulating Tumor Cells

Thank you

Trial Information


In spite of technological advantages in diagnosis and treatment, lung cancer remains one of
the most deadly malignant neoplasias. Moreover, there are no markers for monitoring response
to treatment. The objective of the study is to associate the number of circulating tumor
cells (CTC) before and after treatment and correlate it with tumor response rate,
progression-free survival and overall survival.


Inclusion Criteria:



- Histopathologic diagnosis of non small-cell lung cancer

- Clinical stage IV

- ECOG functional status 0 or 1

- No renal function alteration (GFR >50%)

- No hepatic function alteration (ALT and AST less than 2 times its normal value)

- Leucocytes more than 2,000/mcl

- Hemoglobin more than 10mg/dL

- Platelets more than 100,000/mcl

Exclusion Criteria:

Non-advanced disease

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Response rate, progression-free survival and over-all survival

Outcome Time Frame:

4 years

Safety Issue:

No

Principal Investigator

Oscar Arrieta, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Counsil of Science and Technology

Authority:

Mexico: National Council of Science and Technology

Study ID:

INCAN/OfCA204/SO151/CB451/09

NCT ID:

NCT01052818

Start Date:

July 2007

Completion Date:

Related Keywords:

  • Circulating Tumor Cells
  • Non small-cell lung cancer
  • Circulating tumor cells
  • Carcinoembryonic antigen
  • Cytokeratin
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Neoplastic Cells, Circulating

Name

Location